

A practical guide for providers on helping patients locate Pulmicort (Budesonide) during the 2026 shortage. Includes tools, workflow tips, and alternatives.
The budesonide inhalation shortage is generating a steady stream of calls to your office: patients who can't fill their prescriptions, pharmacies requesting therapeutic alternatives, and parents worried about their child's asthma control. It's a real clinical and operational challenge.
This guide covers practical steps your practice can take to help patients find Budesonide — or get on an effective alternative — with minimal disruption to your workflow.
As of early 2026, here's the supply picture:
Stock levels vary significantly between pharmacies — even within the same city. What's out of stock at one CVS may be available at an independent pharmacy three blocks away.
For the full shortage timeline and background, see our provider shortage briefing.
Understanding the barriers your patients face helps you address them more effectively:
Medfinder for Providers lets you (and your patients) check which pharmacies near them have Budesonide in stock in real time. This single step can eliminate the "call 10 pharmacies" frustration for your patients.
Consider adding the Medfinder link to:
Use Medfinder to identify 2-3 pharmacies in your area that currently have budesonide in stock. When a patient calls about a shortage issue, your staff can proactively suggest these pharmacies — and send the prescription there directly.
Independent pharmacies and hospital outpatient pharmacies are often the most reliable during shortages.
Don't wait until a patient calls in crisis. Develop a practice-level protocol for budesonide substitution:
For detailed alternative guidance, see our provider shortage briefing and the patient-facing alternatives guide.
If switching a patient to an alternative ICS, check their formulary first. Many alternatives may require prior authorization or have step therapy requirements. Some insurers have implemented shortage exceptions — it's worth calling the payer to ask about expedited PA during the active budesonide shortage.
Tips to speed up the PA process:
Patients who are forced to switch pharmacies or formulations may face unexpected costs. Help them prepare:
For a complete breakdown, share our patient guide on saving money on Pulmicort.
Draft a standard message for your patient portal or phone system explaining the current budesonide shortage, what patients should do, and where to find help. This reduces incoming calls and empowers patients to take action.
Sample message points:
Having one staff member (or rotating responsibility) who monitors shortage updates and manages related prescription changes can streamline workflow. This person can check ASHP updates weekly and maintain a list of pharmacies with current stock.
If your practice has a significant pediatric asthma population, proactively identify patients on budesonide inhalation suspension and reach out before they run out. A proactive call or portal message is much more efficient than handling the crisis after they've already missed doses.
The budesonide inhalation shortage is a real burden on practices and patients alike. But with the right tools and a proactive approach, you can minimize treatment gaps and reduce the operational strain on your team.
Start by directing patients to Medfinder for Providers. Have your alternative protocols ready. And communicate early — the patients who hear from you before they're out of medication will have the smoothest experience.
For additional resources, see our guide to helping patients save money on Pulmicort.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.